Prestige Consumer Healthcare PBH Business Segments
| TTM Q4 '26 | TTM Q3 '26 | TTM Q2 '26 | TTM Q1 '26 | TTM Q4 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| International OTC Healthcare | $175.13M-1.5% | $175.63M-0.2% | $179.26M+4.9% | $179.88M+6.6% | $177.75M+6.4% | |
| North American OTC Healthcare | $913.58M-4.8% | $927.98M-1.5% | $931.22M-0.9% | $940.27M-0.4% | $960.01M+0.2% | |
| Total revenues by Product | ||||||
| Analgesics | $113.94M-3.2% | $115.9M+0.5% | $118.85M+3.7% | $118.34M+0.5% | $117.7M+0.2% | |
| Cough & Cold | $101.91M-4.1% | $102.53M-2.8% | $102.53M-6.2% | $104.52M-7.7% | $106.21M-10.8% | |
| Dermatologicals | $125.93M-2.3% | $124.53M-4.7% | $125.54M-1.8% | $125.7M-0.6% | $128.95M-0.1% | |
| Eye & Ear Care | $142.94M-22.0% | $151.81M-15.9% | $158.89M-11.7% | $167.5M-9.0% | $183.32M+2.2% | |
| Gastrointestinal | $259.79M+1.5% | $260.32M+5.5% | $259.85M+8.6% | $255.71M+10.2% | $255.94M+10.5% | |
| Oral Care | $101.05M+6.3% | $100.15M+7.4% | $96.64M+3.2% | $95.96M+3.9% | $95.03M-1.3% | |
| Other OTC | $15.39M+11.7% | $13.88M+6.8% | $13.31M+5.4% | $13.41M+9.7% | $13.78M+14.6% | |
| Women's Health | $227.77M-3.8% | $234.5M+0.5% | $234.86M+0.6% | $239.01M+1.7% | $236.83M-1.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Prestige Consumer Healthcare break its business down?
- Prestige Consumer Healthcare (PBH) reports total revenues by business across 2 parts — International OTC Healthcare and North American OTC Healthcare. Each is extracted from the segment footnotes and tracked over time.
- Where does Prestige Consumer Healthcare's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Prestige Consumer Healthcare's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
